Equity, Bottom-up Analyst, Investics Research

Sameer Taneja

A buy-side analyst with over 18 years of experience investing in Asian markets and specializing in the mid-small cap space, emphasizing value investing in companies with good free cash flows/dividends and long-term holding horizons. 
Exempt Financial Adviser (EFA) under CrossASEAN Research Pte Ltd. It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity, Bottom-up Analyst

Perfect Medical (1830 HK): Postcard from Hong Kong, October 2025

Perfect Medical (1830 HK) H1 FY25 Earnings: Resilient Yield Despite Weak HK Sentiment

Perfect Medical (1830 HK): Gleanings from the Annual Report and Presentation For FY24

Perfect Medical (1830 HK): Resilient FY24 And 12.5% Trailing Dividend Yield

Investics Research

It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity Bottom-up Research

Equity Bottom-Up

Perfect Medical Health / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/perfect-medical-health-management" target="_blank" data-smartkarma-citation="entities:3639:1" rel="noopener">Perfect Medical Health (1830 HK)</a> reported a disastrous FY25 with revenues/profits down 19.1%/34.5% YoY. For H2 FY25, revenues/profits were down 25%/48% YoY. </li>
<li>The company saw a stabilization in its revenues QoQ for H2 FY25, and is now seeing a slight uptick in revenues/profits courtesy of revamped stores ramping up and cost-cutting measures.  </li>
<li>With 23% of its market cap in cash/investments, a PE of 10.4x/8.0x for FY25/FY26e, respectively, the company has an appetizing dividend yield of 12.5% (assuming -4.5% YoY revenue growth). </li>
</ul>



Perfect Medical Health (1830 HK) reported a disastrous FY25 with revenues/profits down 19.1%/34.5% YoY. For H2 FY25, revenues/profits were down 25%/48% YoY. 
The company saw a stabilization in its revenues QoQ for H2 FY25, and is now seeing a slight uptick in revenues/profits courtesy of revamped stores ramping up and cost-cutting measures.  
With 23% of its market cap in cash/investments, a PE of 10.4x/8.0x for FY25/FY26e, respectively, the company has an appetizing dividend yield of 12.5% (assuming -4.5% YoY revenue growth). 


Perfect Medical (1830 HK): Green Shoots Emerging After A Disastrous FY25